Boston Scientific's Farapulse pulsed field ablation system has redefined the electrophysiology market with the fastest medtech product launch in recent history, gaining clear share leadership against Medtronic Affera and J&J Varipulse. WATCHMAN left atrial appendage closure continues to penetrate atrial fibrillation patient population. Structural heart and EP combine for double-digit growth segment. Operating leverage strong.
Thesis reviewed May 29, 2026
Boston Scientific Corporation is headquartered in United States, which is currently showing moderate signals.
🇺🇸United States48EARLYView United States risk detail →🏥Healthcare35NEUTRAL| Ticker | Company | Score | Gap | Signal Δ | Action |
|---|---|---|---|---|---|
| TMO | Thermo Fisher Scientific Inc. | 38 | +11% | ↓3% | EARLY |
| SYK | Stryker Corporation | 38 | +15% | ↓3% | EARLY |
| TEVA | Teva Pharmaceutical Industries Ltd. | 38 | +9% | ↓3% | NEUTRAL |
| ELV | Elevance Health Inc. | 38 | +7% | ↓3% | NEUTRAL |
| CI | The Cigna Group | 38 | +9% | ↓3% | NEUTRAL |
| HCA | HCA Healthcare Inc. | 38 | +9% | ↓3% | EARLY |
| DHR | Danaher Corporation | 38 | +11% | ↓3% | EARLY |
Investors who hold BSX may also have indirect exposure through these country funds.
Farapulse accounts for 40%+ of EP ablation procedures in adopted accounts
Boston Scientific raises FY26 organic growth guidance to 14%+
WATCHMAN FLX Pro launch drives accelerating LAAC adoption
Estimates · Yahoo Finance · Not audited figures
| Politician | Party | Type | Amount | Trade Date | Return |
|---|---|---|---|---|---|
| Gilbert CisnerosCA | D | Buy | $1k–$15k | Feb 10, 26 | -32.8% |
| Gilbert CisnerosCA | D | Buy | $1k–$15k | Jan 30, 26 | -35.4% |
| Markwayne Mullin | Buy | $15k–$50k | Dec 29, 25 | -45.1% | |
| John Boozman | Sell | $1k–$15k | Dec 17, 25 | -48.7% | |
| Gilbert CisnerosCA | D | Sell | $1k–$15k | Dec 24, 25 | -49.5% |
| John Boozman | Buy | $1k–$15k | Feb 13, 25 | -52.1% |